Verano Holdings (VRNO) Income from Continuing Operations (2021 - 2026)

Verano Holdings' (VRNO) quarterly Income from Continuing Operations came in at 17823000.0 in Q1 2026, down 54.78% year-on-year from 39414604.38 in Q1 2025, and up 90.28% on a QoQ basis from 183411000.0 in Q4 2025.

Verano Holdings (VRNO) Income from Continuing Operations (2021 - 2026) Analysis & Trends

Verano Holdings (VRNO) has 6 years of Income from Continuing Operations data on file, last reported at 17823000.0 in Q1 2026.

  • On a quarterly basis, Income from Continuing Operations fell 54.78% year-over-year to 17823000.0 in Q1 2026; TTM through Mar 2026 was 264216000.0, a 24.2% increase from a year earlier, with the FY2025 full-year figure at 257908000.0, up 24.56% from the prior year.
  • Income from Continuing Operations for Q1 2026 stood at 17823000.0, up from 183411000.0 in the prior quarter.
  • Over the last five years, Income from Continuing Operations for VRNO reached as high as 45866000.0 in Q1 2022 and fell as low as 272706000.0 in Q4 2024.
  • Historically, Income from Continuing Operations has averaged 56354235.29 across 5 years, with a median of 19150000.0 in 2025.
  • On a YoY basis, Income from Continuing Operations climbed as much as 66.72% in 2022 and fell as far as 3065.98% in 2022.
  • Year by year, Income from Continuing Operations stood at 216110000.0 in 2022, then soared by 64.24% to 77286000.0 in 2023, then sank by 252.85% to 272706000.0 in 2024, then jumped by 32.74% to 183411000.0 in 2025, then soared by 90.28% to 17823000.0 in 2026.
  • Per Business Quant data, the three most recent Income from Continuing Operations figures were 17823000.0 in Q1 2026, 183411000.0 in Q4 2025, and 43832000.0 in Q3 2025.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Income (Continuing) (Qtr)
1 Haleon 87.22 Bn 85.35 Bn - -
2 Teva Pharmaceutical Industries 39.60 Bn 35.87 Bn 1.97 Bn 370.00 Mn
3 Zoetis 31.46 Bn 29.52 Bn 1.62 Bn 601.00 Mn
4 Takeda Pharmaceutical 26.49 Bn 22.44 Bn 4.39 Bn -3.58 Bn
5 United Therapeutics 23.03 Bn 20.88 Bn 648.10 Mn 274.90 Mn
6 Universe Pharmaceuticals 23.03 Bn -10.56 Bn - -
7 Viatris 20.90 Bn 19.09 Bn 1.16 Bn 176.40 Mn
8 Neurocrine Biosciences 17.50 Bn 16.19 Bn 800.70 Mn 197.90 Mn
9 Elanco Animal Health 12.33 Bn 11.91 Bn 785.00 Mn 57.00 Mn
10 Verano Holdings 2.02 Bn 1.94 Bn 98.98 Mn -17.82 Mn

Historic Data

Download Data
DateValue
Mar 31, 2026 -17.82 Mn
Dec 31, 2025 -183.41 Mn
Sep 30, 2025 -43.83 Mn
Jun 30, 2025 -19.15 Mn
Mar 31, 2025 -11.52 Mn
Dec 31, 2024 -272.71 Mn
Sep 30, 2024 -42.57 Mn
Jun 30, 2024 -21.76 Mn
Mar 31, 2024 -4.82 Mn
Dec 31, 2023 -77.29 Mn
Sep 30, 2023 -17.76 Mn
Jun 30, 2023 -13.06 Mn
Mar 31, 2023 -9.24 Mn
Dec 31, 2022 -216.11 Mn
Sep 30, 2022 -42.99 Mn
Jun 30, 2022 -9.85 Mn
Mar 31, 2022 45.87 Mn
Dec 31, 2021 -6.83 Mn
Sep 30, 2021 -11.96 Mn
Jun 30, 2021 -29.59 Mn